{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:40:04Z","timestamp":1783413604761,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s12072-014-9583-z","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T14:50:53Z","timestamp":1412088653000},"page":"142-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma"],"prefix":"10.1007","volume":"9","author":[{"given":"Yoko","family":"Yashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinpei","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"9583_CR1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0168-8278(02)00297-0","volume":"37","author":"SA Khan","year":"2002","unstructured":"Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806\u2013113","journal-title":"J Hepatol"},{"key":"9583_CR2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2007-1007302","volume":"14","author":"JN Vauthey","year":"1994","unstructured":"Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis. 1994;14:109\u2013114","journal-title":"Semin Liver Dis"},{"key":"9583_CR3","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","volume":"366","author":"SA Khan","year":"2005","unstructured":"Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303\u20131314","journal-title":"Lancet"},{"key":"9583_CR4","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.3748\/wjg.15.4240","volume":"15","author":"M Aljiffry","year":"2009","unstructured":"Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma.1990\u20132009. World J Gastroenterol. 2009;15:4240\u20134262","journal-title":"World J Gastroenterol"},{"key":"9583_CR5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/annonc\/mdf262","volume":"13","author":"M Cantore","year":"2002","unstructured":"Cantore M, Rabbi C, Guadagni S, Zamagni D, Aitini E. Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma. Ann Oncol. 2002;13:1687\u20131688","journal-title":"Ann Oncol"},{"key":"9583_CR6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/cncr.21832","volume":"106","author":"S Obi","year":"2006","unstructured":"Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato A et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106:1990\u20131997","journal-title":"Cancer"},{"key":"9583_CR7","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/cncr.26648","volume":"118","author":"K Kasai","year":"2012","unstructured":"Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K et al. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon \u03b1-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012;118:3302\u20133310","journal-title":"Cancer"},{"key":"9583_CR8","first-page":"518","volume":"54","author":"M Kuroda","year":"2007","unstructured":"Kuroda M, Kobayashi Y, Urawa N, Yamamoto M, Mifuji R, Araki J et al. Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. Hepatogastroenterology. 2007;54:518\u2013521","journal-title":"Hepatogastroenterology"},{"key":"9583_CR9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1872-034X.2011.00905.x","volume":"42","author":"M Monden","year":"2012","unstructured":"Monden M, Sakon M, Sakata Y, Ueda Y, Hashimura E. FAIT research group. 5-fluorouracil arterial infusion\u00a0+\u00a0interferon therapy for highly advanced hepatocellular carcinoma: a multicenter, randomized, phase II study. Hepatol Res. 2012;42:150\u2013165","journal-title":"Hepatol Res"},{"key":"9583_CR10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.3109\/00365520903367262","volume":"44","author":"JR Eun","year":"2009","unstructured":"Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol. 2009;44:1477\u20131486","journal-title":"Scand J Gastroenterol"},{"key":"9583_CR11","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/cncr.20964","volume":"103","author":"M Cantore","year":"2005","unstructured":"Cantore M, Mambrini A, Fiorentini G, Rabbi C, Zamaqni D, Caudana R et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer. 2005;103:1402\u20131407","journal-title":"Cancer"},{"key":"9583_CR12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00000658-199604000-00007","volume":"223","author":"CH Su","year":"1996","unstructured":"Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg. 1996;223:384\u2013394","journal-title":"Ann Surg"},{"key":"9583_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000318020","volume":"79","author":"E Suzuki","year":"2010","unstructured":"Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S et al. Treatment efficacy\/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology. 2010;79:39\u201345","journal-title":"Oncology"},{"key":"9583_CR14","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/cncr.23787","volume":"113","author":"JH Kim","year":"2008","unstructured":"Kim JH, Yoon HK, Sung KB, Ko GY, Gwon DI, Shin JH et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer. 2008;113:1614\u20131622","journal-title":"Cancer"},{"key":"9583_CR15","first-page":"957","volume":"21","author":"C Chuaysri","year":"2009","unstructured":"Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep. 2009;21:957\u2013969","journal-title":"Oncol Rep"},{"key":"9583_CR16","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1245\/s10434-009-0568-4","volume":"16","author":"H Okabe","year":"2009","unstructured":"Okabe H, Beppu T, Hayashi H, Horino K, Masuda T, Komori H et al. Hepatic stellate cells may relate to progression of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2009;16:2555\u20132564","journal-title":"Ann Surg Oncol"},{"key":"9583_CR17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cgh.2009.08.023","volume":"7","author":"AE Sirica","year":"2009","unstructured":"Sirica AE, Dumur CI, Campbell DJ, Almenara JA, Ogunwobi OO, Dewitt JL. Intrahepatic cholangiocarcinoma progression: prognostic factors and basic mechanisms. Clin Gastroenterol Hepatol. 2009;7:68\u201378","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9583_CR18","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al. ABC-02 trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u20131281","journal-title":"N Engl J Med"},{"key":"9583_CR19","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1172\/JCI63065","volume":"122","author":"S Sekiya","year":"2012","unstructured":"Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Invest. 2012;122:3914\u20133918","journal-title":"J Clin Invest"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-014-9583-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-014-9583-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-014-9583-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T03:37:18Z","timestamp":1559446638000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-014-9583-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["9583"],"URL":"https:\/\/doi.org\/10.1007\/s12072-014-9583-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}